Speciality: Rheumatology
Description:
A warm welcome to all the medical practitioners in this interesting session of managing psoriatic arthritis with JAK inhibitors.
Psoriatic arthritis is a chronic inflammatory arthritic disease. The patients undergo severe pain with psoriatic arthritis. Being a rheumatic disease it needs a proper attention to the inflammatory pathways or rather targeting inflammatory molecules which can alter the responses and help in getting a potential cure of the disease.
The speakers Dr Bhupendra Vaishnav, Dr. Amit Sharma have provided elaborative knowledge on the immunological management of psoriatic disease with the use of JAK inhibitors.
Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues.
The webinar will help in gaining important insights on JAK inhibiting drugs in controlling rheumatoid arthritis. JAK inhibitors work as a competitive inhibitor of JAK that binds to adenosine triphosphate in the kinase domain, which eventually helps in controlling rheumatoid arthritis.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Inner Thoughts of Leonard Bernstein, the "Maestro".
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC
4.
Parents, teachers at Missouri school want answers after string of cancer diagnoses
5.
A promising medication could slow brain tumors in children.
1.
Future-Ready Cancer Screening: What Every Clinician Should Know in 2025
2.
Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies
3.
Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances
4.
Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases
5.
Generative AI for Adaptive Oncology Trial Design
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation